Moleculin Biotech completes dosing in Part A of Miracle trial; data readout on track for Q1 2027
MBRX•Moleculin Biotech completed dosing in Part A of its Miracle trial, with a data readout on track for Q1 2027.
1. Trial update
Moleculin Biotech said it completed dosing in Part A of the Miracle trial. The data readout remains on track for Q1 2027.
